INTELLIGENT BIO SOLUTIONS INC. Q4 FY2022 earnings call

• Achievements with saliva Glucose Biosensor: Completed sample collection and analysis in a study of oral fluid and blood glucose, results were encouraging. Moving into final design and verification phase with two key clinical studies to refine sampling protocols and Biosensor performance. • Manufacturing facility: Selected site at University of Newcastle for a new Biosensor manufacturing facility, construction to commence by end 2022, with equipment deliveries ongoing. • Engagement with Intelligent Fingerprinting Limited: Executed exclusivity agreement for point-of-care fingerprint, sweat-based drug screening technology; discussions ongoing for potential acquisition. • New Director of Operations: Welcomed Peter Passaris, with 18 years of manufacturing and enterprise experience, to manage Newcastle SRA and product development activities.

No detailed breakdown of product segments with financial performance and revenue contributions provided in the transcript.

• Cash, cash equivalents, and marketable securities totaled ~$8.2 million as of June 30, 2022, sufficient to cover expenses and capital requirements into the second half of 2023. • Flexibility in cash burn due to clumpy nature of R&D and equipment expenditure; anticipation of updating on cash flow impact of IFP deal once completed. • Discussions ongoing regarding building facility with university acting as tenant, with equipment expenditure timing and government grants considered.

• Forward-looking statements involve known and unknown risks, uncertainties, and other factors, including ability to develop and commercialize diagnostic tests, realize commercial benefit from partnerships/collaborations, and secure regulatory approval.

Q: Discuss the sticking points and details of the Intelligent Fingerprinting deal extension.

A: Discussions ongoing, long and detailed process with many fine points addressed; pressing forward with negotiations.

Q: Explain sampling protocols for the Glucose Biosensor.

A: Initial study was on saliva using mass spectrometer, now proceeding to studies on Biosensor to address variables affecting glucose levels and assess accuracy/reproducibility.

Q: Regarding interim CEO role, will Steven assume full CEO role?

A: Focus on completing IFP deal first; once deal progresses, will evaluate Chief Executive position with management and Board representation from IFP considered.

Q: Talk about cash burn and impact of IFP deal.

A: Cash burn has clumpy nature of expenditure; flexibility in timing of expenditure, and anticipation of releasing pro formas on cash flow impact once IFP deal is completed.

Q: Cash flow related to building facility?

A: University to build facility, we'll be tenant; equipment expenditure has timing, with government grants considered, and flexibility in cash flow due to project-based expenditure.